- Lead. Eli Lilly shares jumped more than seven percent on June 26 after the European Medicines Agency’s drug evaluation committee issued a positive opinion recommending approval of Jaypirca — the company’s BTK inhibitor — for adults with chronic lymphocytic leukemia regardless of how many prior therapies they have had.
- Fact. The recommendation covers all lines of therapy, including patients who have previously used other BTK inhibitors, a broader label than many analysts expected and the key driver of the market reaction.
- Stake. With a European Commission formal decision expected within one to two months and a US FDA ruling anticipated in the second half of 2026, Jaypirca is approaching global approval in a CLL market that sees roughly 100,000 new diagnoses each year.
Eli Lilly (NYSE: LLY) closed at $1,208.12 on June 26, 2026, a gain of $80.43 or 7.13% on the session, after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy.
What the CHMP recommended
Pirtobrutinib is a non-covalent Bruton tyrosine kinase (BTK) inhibitor, distinguished from earlier BTK inhibitors by its ability to work even in patients whose cancer has become resistant to covalent BTK inhibitors such as ibrutinib. That distinction is central to the breadth of the CHMP’s recommendation: the opinion covers CLL patients whether or not they have received a prior BTK inhibitor — an unusually wide scope.
The recommendation draws on two pivotal trials. BRUIN CLL-314 enrolled 662 patients and compared pirtobrutinib at 200 mg once daily against ibrutinib in treatment-naïve and previously treated patients who had not previously used a BTK inhibitor. BRUIN CLL-313 enrolled 282 patients and compared pirtobrutinib against chemoimmunotherapy (BR) in treatment-naïve CLL patients — the first Phase 3 study of a non-covalent BTK inhibitor exclusively in this population, according to data published in The Journal of Clinical Oncology.
What comes next
A positive CHMP opinion typically leads to a formal European Commission marketing authorisation within one to two months. In the United States, where CLL carries approximately 4.92 diagnoses per 100,000 people per year in Europe and a comparable rate globally, an FDA decision is expected before the end of 2026. Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, described the CHMP opinion as “a step toward an important global approval for Jaypirca in this indication.”
The move extends a run of regulatory momentum for Lilly’s oncology portfolio. The company has positioned Jaypirca as a differentiated option within the competitive CLL treatment landscape, where patients who progress on first-generation BTK inhibitors have historically had limited options. A broad all-lines label in Europe would materially expand the addressable patient population ahead of the US decision, which will set the ceiling on global peak sales projections.